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Aminoacyl-tRNA synthetases (AARSs) catalyze ami-
noacylation of tRNAs in the cytoplasm. Surpris-
ingly, AARSs also have critical extracellular and
nuclear functions. Evolutionary pressure for new
functions might be manifested by splice variants
that skip only an internal catalytic domain (CD) and
link noncatalytic N- and C-terminal polypeptides.
Using disease-associated histidyl-tRNA synthetase
(HisRS) as an example, we found an expressed
171-amino acid protein (HisRSDCD) that deleted
the entire CD, and joined an N-terminal WHEP to
the C-terminal anticodon-binding domain (ABD).
X-ray crystallography and three-dimensional NMR
revealed the structures of human HisRS and
HisRSDCD. In contrast to homodimeric HisRS,
HisRSDCD is monomeric, where rupture of the
ABD’s packing with CD resulted in a dumbbell-like
structure of flexibly linked WHEP and ABD domains.
In addition, the ABD of HisRSDCD presents a distinct
local conformation. This natural internally deleted
HisRS suggests evolutionary pressure to reshape
AARS tertiary and quaternary structures for repur-
posing.
INTRODUCTION
Although aminoacyl-tRNA synthetases (AARSs) catalyze the
aminoacylation of tRNAs in the first step of protein synthesis in
the cytoplasm, numerous reports document their activities in
nuclear and extracellular locations, where translation does not
occur (Fu et al., 2012; Guo et al., 2010; Kim et al., 2011; Martinis
and Joy Pang, 2007; Park et al., 2008, 2012; Sajish et al., 2012;
Xu et al., 2012). These activities include major roles in regulating
angiogenesis (Xu et al., 2012; Yao et al., 2012), inflammatory
responses (Arif et al., 2009; Fu et al., 2012; Lee et al., 2012),
mTOR signaling (Bonfils et al., 2012; Han et al., 2012), and tumor
growth (Dorrell et al., 2007; Park et al., 2012). In at least some1470 Structure 20, 1470–1477, September 5, 2012 ª2012 Elsevier Ltinstances, a fragment produced by natural proteolysis is the
active factor. These fragments typically remove an external N-
or a C-terminal peptide and leave intact all or most of the internal
catalytic domain (CD). Indeed, a CD pocket is used by a natural
tryptophanyl-tRNA synthetase (TrpRS) fragment to bind to the
extracellular domain of VE-cadherin on endothelial cells to pre-
vent the assembly of blood vessels (Zhou et al., 2010). These
observations suggest evolutionary pressures to expropriate
AARSs for functions outside of the cytoplasm, perhaps because
of their close association with the origin and creation of the
genetic code, and the latter’s capacity to adopt functions and
species in response to changes in the environment (Giege´,
2008).
With that consideration in mind, we thought that a clear mani-
festation of these selective pressures and their consequences
would be the appearance of forms of AARSs that could not arise
from proteolysis, but rather from alternative splicing that specif-
ically removed the internal CD and little else. The one well-
studied example of an AARS splice variant, mini TrpRS, removes
the N-terminal 48 amino acids and leaves the entire CD intact
(Wakasugi et al., 2002). It has full catalytic activity. An exquisitely
tailored deletion that only excised the CD would suggest strong
selective pressures to create forms that were catalytically inac-
tive and therefore presumably designed for repurposing. The
structural consequences of an internal deletion of this sort are
unknown. To investigate this question, we chose HisRS, which
is associated with idiopathic inflammatory myopathies (IIM)
and interstitial lung disease (ILD) (Bernstein et al., 1984; Jura
et al., 2007). Our rationale was that the roots of this disease
association could be related to a variant of HisRS that was de-
signed for another function, which itself was connected to
inflammatory responses.
We identified the alternatively spliced forms of the gene for
human HisRS by the high-throughput deep-sequencingmethod,
and discovered a splice variant HisRSDCD that skips exons en-
coding the entire CD. This splice variant encodes an endoge-
nously expressed protein with the N-terminal WHEP domain
joined to the C-terminal ABD. It showed enriched expression in
human lung tissue and interacted with Jo-1 antibodies of human
myositis patients, implicating the connection to the autoimmune
diseases IIM and ILD. Employing crystallographic and NMR
techniques, we revealed distinct structures of human HisRSd All rights reserved
Figure 1. Identification and Validation of a
HisRS Splice Variant that Skips the Entire
Catalytic Domain
(A) Schematic illustration of human HisRS protein
and the identified exon-skipping splicing events.
Human HisRS is composed of an N-terminal
WHEP domain, a core catalytic aminoacylation
domain and a C-terminal anticodon binding
domain. The three conserved sequence motifs in
its core active site are indicated by green, blue and
brown bars, respectively. The mRNA transcript of
the gene for human HisRS is shown below and
aligns with its encoded protein. Canonical exons
are drawn in scale to the nucleotide length and are
labeled consecutively. The splicing events identi-
fied by deep sequencing in the current study
are illustrated by dashed lines to indicate non-
canonical exon junctions. Exon junctions that were
not annotated in the AceView database, including
DE3-10 (HisRSDCD), are indicated by red lines,
and the previously reported ones are shown in
gray. Targeting sites of the PCR primers are indi-
cated by blue arrows and those of qPCR primers
by green arrows. The primer sequences are shown
in Table S2.
(B) Validation by PCR of the splice variant that
skips exons 3 to 10. PCR was performed using
cDNA of IMR-32 neuronal cells and a pair of
primers targeting 50-UTR/Exon1 (FP) and 30-UTR
(RP) of the gene for HisRS. PCR products were separate by agarose gel electrophoresis. Lane 1: PCR by FP and RP, Lane 2: PCR by primers targeting GAPDH
as control.
(C) Sequencing result specifically shows the Exon2-11 junction in the HisRSDCD transcript.
(D) Schematic of protein products of human HisRS FL and HisRSDCD. The protein product of splice variant HisRSDCD has the entire aminoacylation domain
(aa61-398) removed due to skipping of exons 3 to 10 and therefore directly connects the WHEP domain to the ABD.
(E) Detection of endogenous HisRSDCD protein by western blot analysis. HisRSDCD protein was detected in whole extracts of IMR-32 cells using antibodies
against, separately, the N- and C terminus of HisRS (N-mAb, monoclonal antibody against HisRS aa1-97; C-pAb, polyclonal antibody against HisRS C terminus).
Total lysates of 293T cells transiently transfected with a HisRSDCDconstruct were run in parallel with IMR-32 cell extracts to serve as a control that shows the size
of HisRSDCD. The expected running position of the HisRSDCD protein is indicated by an arrow.
See also Figure S1 and Tables S1 and S2.
Structure
Human HisRS and Internally Deleted Splice Variantand HisRSDCD. Different from homodimeric HisRS, HisRSDCD
is monomeric. Release of the ABD’s packing with CD resulted
in a dumbbell-like structure of flexibly linked WHEP and ABD
domains and the ABD presents a distinct local conformation,
readily allowing specific interaction partners and non-conven-
tional biological activities. Our study extends the understanding
of structure and function of the AARS family of ancient enzymes
and suggests evolutionary pressure to reshape AARS tertiary
and quaternary structures for repurposing.
RESULTS AND DISCUSSION
Comprehensive Identification of Alternative Splice
Variants of Human HisRS by Deep Sequencing of
AARS-Transcriptome Enriched cDNA
Based on its sequence, the 509 amino acid human HisRS is
a class II tRNA synthetase composed of a core CD, a C-terminal
anticodon binding domain, and an N-terminal WHEP domain
(Figure 1A). The catalytic aminoacylation domain is shared by
all class II tRNA synthetases, which have a characteristic
7-stranded b-structure and flanking a helices, with three class-
defining conserved sequence motifs (Carter, 1993; Li et al.,
2011). The WHEP domain is a 50 amino acid, helix-turn-helix
motif present in one or more copies in tryptophanyl-, histidyl-,Structure 20, 1470–14glutamyl-prolyl-, glycyl-, and methionyl-tRNA synthetases, and
takes its name from the first three (W, H, and EP). This domain
was appended to specific AARSs as the tree of life ascended
from lower to higher eukaryotes. It first appeared in HisRS in
nematodes and was retained ever since (Guo et al., 2010).
Although the functional role of the HisRSWHEP domain remains
unclear, it harbors epitope(s) targeted by autoantibodies of
patients with IIM/ILD (Jura et al., 2007; Martin et al., 1995; Raben
et al., 1994). Until now, no crystal structures of human HisRS or
expressed splice variant proteins have been reported.
For a comprehensive identification of alternatively spliced
forms of HisRS, we employed the high-throughput transcrip-
tome sequencing technique. Because whole transcriptome se-
quencing limits the read-depth of the exome of individual genes,
we developed an amplification-based transcriptome sequenc-
ing method for a more thorough discovery of splice variants.
Previous work annotated a number of alternative mRNA variants
of the gene for human HisRS by sequencing of cDNA clones
(Thierry-Mieg and Thierry-Mieg, 2006). However, as annotated
in the AceView database, these splice variants include truncation
of the 50 or 30 ends, overlapping exons with different boundaries,
splicing versus retention of introns, and the presence or absence
of cassette exons. Also, expression of either recombinant or
natural versions of these potential splice variants has never77, September 5, 2012 ª2012 Elsevier Ltd All rights reserved 1471
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Human HisRS and Internally Deleted Splice Variantbeen investigated. The RNAwas reverse transcribed to cDNA by
primers specific to the target gene, and then amplified using
primers targeting their exon regions at positions close to the
exon-exon junctions. This method allowed sensitive detection
of low-abundant splice variants and was mainly designed for
discovery of splice variants having exon-skipping events.
A complete and more comprehensive description of the
AARS-specific transcriptome approach will be published sepa-
rately. In brief, the transcriptome for HisRS was first enriched
with RNA of human adult brain, fetal brain, total leukocytes, Ju-
rkat T, Raji B lymphocytes, or THPmonocytes, and then followed
with deep sequencing. When compared to other human exome
sequencing efforts, this method was found to significantly
enhance the sequencing depth, yielding a > 1000 fold increase
in sequencing reads after enrichment. The exon-skipping events
in the gene for HisRSwere concentrated on the region of exons 3
to 10 that encode the aminoacylation domain (Figure 1A; Table
S1 available online). If these splice variants give rise to protein
products, the generated HisRS isoforms are expected to have
partially or completely disrupted enzymatic activity. Thus, these
splice variants may be endowed with novel biological functions
through new domain compositions and structures. Possibly,
they could be immunogenic or associated with pathologies
when abnormally regulated or secreted.
Validation and Expression Analysis of a Splice Variant
HisRSDCD that Skips the Entire Catalytic Domain
HisRSDCD, the splice variant with the largest internal deletion,
has the skipping of exons 3 to 10 (DE3-10) that encode the entire
aminoacylation domain (Figure 1A).We foundHisRSDCDwith 50
sequencing reads in human adult brain and seven reads in Jurkat
T lymphocyte (Table S1). The putative protein product would
carry no aminoacylation activity, but retained the N-terminal 60
amino acids and the C-terminal ABD. To further verify this splice
variant and obtain a more complete sequence of its transcript,
the PCR was performed. Because HisRSDCD was identified
with highest reads in the adult brain, we employed a human
neuronal cell line IMR-32 for its validation. The PCR reaction
with the cDNA template of mRNA from IMR-32 cells, together
with a pair of primers targeting the 50-UTR/Exon1 and 30-UTR
regions of the gene for HisRS (FP and RP), amplified a product
with a size shorter than the expected band of the full-length
(FL) transcript (Figures 1A and 1B; Table S2). This shorter PCR
product was subjected to sequencing, and confirmed to bear
the Exon2-11 junction of HisRSDCD (Figure 1C). Based on the
sequence of the PCR product, the HisRSDCD transcript has
exons 3 to 10 (1014 nt) removed, but still retains the 50- and
30-UTR region and the remaining exons of the FL transcript. It
is therefore expected to translate into a protein with the in-frame
deletion of the entire aminoacylation domain (aa61–398), and
thereby join the N-terminal WHEP domain to the C-terminal
ABD (Figure 1D).
We employed the SYBR green quantitative real-time PCR
(qPCR) method to examine the mRNA expression level of native
HisRS and of HisRSDCD transcripts in various human tissues.
We first optimized qPCR reactions to produce specific PCR
products with high efficiency. All amplified products were de-
signed to cover exon junctions and to exclude amplicons derived
from intronic regions. After optimization, a pair of primers1472 Structure 20, 1470–1477, September 5, 2012 ª2012 Elsevier Lttargeting Exon9 and Exon10 (qFP1 and qRP1) was used for
amplification of the FL transcripts (Figure 1A; Table S2). For
HisRSDCD a pair of primers targeting Exon2 and Exon11
(qFP2 andqRP2)was employed in qPCR reactions having a short
extension time (30 s), which thereby attenuated amplification of
the longer FL transcript. Using the optimized qPCR reactions,
the presence of the HisRS transcripts was analyzed across 13
human tissues, including those of the immune system (total
leukocytes, bone marrow, spleen), circulatory system (lung,
heart, kidney), digestive system (liver, pancreas, small intestine,
colon), and others (thyroid, adipose cells, skeletal muscle). The
FL transcript for HisRS was found to be evenly distributed
among the various tissues that were tested, with no more than
three times deviation from the median value (Figure S1A). In
contrast, HisRSDCD exhibited a differential mRNA expression
profile, with the mRNA level highest in lung (about 11-fold above
the median level, Figure S1B), and second highest in spleen
(about 5-fold above the median). Although a causal relationship
to IIM/ILD cannot be inferred from these results, it is nonetheless
of interest to note that the mRNA expression of HisRSDCD
relative to HisRS FL is prominently higher in lung than in other
tissues (Figure S1C). It has been suggested that the lung is the
site of disease initiation in Jo-1 (HisRS) autoantibody associated
ILD (Danoff and Casciola-Rosen, 2011).
Next, we used western blot methods to detect the HisRSDCD
splice variant. For this purpose, we used antibodies raised
against the N- and, separately, the C-terminal region. In view
of the relatively small amounts of the mRNAs that correspond
to these splice variants, and due to the difficulty in obtaining
adequate amounts of human tissues, human cell lines cultured
in vitro were employed. Because the HisRSDCD transcript was
detected in the total RNA of IMR-32 cells, its protein product
was probed using total cell extracts of IMR-32 cells with amono-
clonal antibody raised against the N-terminus (aa1-97) of human
HisRS, and a polyclonal antibody generated by a peptide from
the C terminus. Both antibodies reacted with the same species
having a molecular weight of about 20 kDa (Figure 1E; see also
Figure S1D). The size of this protein corresponds to the recom-
binant HisRSDCD protein overexpressed in HEK293T cells.
Consistent with the relatively low amounts of mRNA that have
been annotated, HisRSDCD is clearly in much lower abundance
(estimated as slightly above 1% of HisRS FL on western blots
probed with the same antibodies).
Structure Determination of Human HisRS by X-Ray
Crystallography
Crystal structures of Escherichia coli and Thermus thermophilus
and of eukaryotic parasites Trypanosoma brucei and Trypano-
soma cruzi in apo and histidine- or His-AMP- bound forms
have been published (Aberg et al., 1997; Arnez et al., 1995; Mer-
ritt et al., 2010). All are a2 dimers and, as expected for a class II
synthetase, all have the characteristic and well conserved anti-
parallel b sheet fold flanked by a helices in the CD. The HisRSs
all have an a/b fold in the anticodon binding domain. The adenine
binding pocket and the topology of an extra domain inserted
between the characteristic conserved motifs 2 and 3 of the class
II AARS catalytic core is substantially different in bacterial and
eukaryote parasitic forms of the enzyme. So far no structure
has been reported for a higher eukaryote form of HisRS.d All rights reserved
Figure 2. Structure Determination of Human HisRS by X-Ray Crystallography
(A) Optimization of the boundary of humanHisRS for high quality crystals. The amino acid range included in eachmutant and the corresponding crystal resolutions
are shown. The three conserved sequence motifs as well as the insertion domain in the aminoacylation domain are indicated by colored bars and labeled below.
(B) Ribbon diagram of the 2.4 A˚ crystal structure of HisRS D1-53_507-509 (blue: CD, green: ABD). The secondary structure a helices and b strands are
consecutively labeled, and the amino acids composing these structural elements are shown in detail in Figure S2D.
(C) Structure comparison of HisRSs of different species including human, trypanosoma (T. brucei, PDB: 3HRI), archaea (T. acidophilum, 1WU7), and bacterium
(S. aureus, 1QE0).
(D) Superposition of the insertion domains of human, trypanosoma and archaea shows differences in the respective orientations of this domain. The a helices
in the insertion domain of human HisRS are labeled, and the corresponding amino acid sequence and the alignment among different species are shown in
Figure S2D.
See also Table 1 and Figure S2.
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Human HisRS and Internally Deleted Splice VariantPurified recombinant human HisRS protein aggregated in the
normal buffer conditions we used. By mapping cysteines in the
human HisRS sequence to the known structures of T. brucei
and T. cruzi HisRS, we found that two cysteines (C507 and
C509) at the very C terminus may be solvent-exposed and
non-specifically form intermolecular disulfide bonds. Therefore,
we removed (from the HisRS-encoding recombinant gene) three
residues at the C terminus (Figure 2A). Indeed, this truncation
mutant D507-509 did not aggregate on PAGE gels, even without
added reducing agent such as DTT. Using this C-terminal trun-
cation mutant we obtained large crystals, which diffracted to
3.1 A˚ resolution (Figure S2A). The space group was determined
to be P41212 with the unit cell dimensions a = b = 100.4 A˚, c =
257.1 A˚ (Table 1). The crystal structure was solved by molecular
replacement using T. brucei HisRS (Protein Data Bank [PDB]:
3HRI) as the template.Structure 20, 1470–14In the crystal structure of human HisRS D507-509 (PDB:
4G84), the N-terminal WHEP domain is not visible, indicating
that this domain is not tightly packed with the structural core
(Figure S2B). The loose packing of the N-terminal domain is
also supported by a previous study of the trypanosomal HisRS,
which showed that its N-terminus was amenable to enzymatic
cleavage during expression (Merritt et al., 2010). To further
improve crystal quality, we optimized the boundary of HisRS
by removing the flexible N-terminal region in different mutants
and achieved a crystal structure at 2.4 A˚ resolution with the dele-
tion mutant D1-53_507-509 (Figures 2A and S2A). The space
group was determined to be P41212 with the unit cell dimensions
a = b = 93.5 A˚, c = 254.5 A˚ (Table 1). This crystal form has the
same space group and similar unit cell dimensions as the
previous one, suggesting that the D1-53_507-509 mutant keeps
the same conformation and crystal packing as the D507-50977, September 5, 2012 ª2012 Elsevier Ltd All rights reserved 1473
Table 1. Statistics of Data Collection and Model Refinement of Human HisRS Crystal and NMR Structures
Crystal Structures of HisRS Variants Family of 20 NMR Structures of HisRSDCDa
HisRS D507-509 HisRS D1-53_D507-509 NMR Distance and Dihedral Constraints
Data collection Total NOE 2,397
Space group P41212 P41212 Intra-residue 978
Unit cell parameters (A˚) a = b = 100.4, c = 257.1 a = b = 93.5, c = 254.5 Inter-residue
Resolution range (A˚) 50–3.1 (3.15–3.1)b 50–2.4 (2.44–2.4) Sequential (ji – jj = 1) 491
No. of unique reflections 24,210 (1,191) 45,571 (2,212) Medium-range (ji – jj < 4) 404
Redundancy 5.5 (5.6) 6.1 (5.8) Long-range (ji – jj > 5) 929
I/s 22.6 (2.4) 21.8 (2.3) Hydrogen bonds 148
Completeness (%) 98.8 (99.9) 99.8 (99.9) Total dihedral angle restraints 216
Rmerge (%)
c 6.9 (69.6) 7.4 (67.9) Structure statistics
Structure refinement Violations (mean and s.d.)
Resolution (A˚) 50–3.1 (3.2–3.1) 50–2.4 (2.49–2.4) Distance constraints (A˚) 0.001 ± 0.001
Rcryst / Rfree (%)
d 27.1 (34.4) / 32.7 (40.0) 19.1 (26.8)/25.0 (35.1) Dihedral angle constraints () 0.574 ± 0.063
Rmsd bonds (A˚)/angles () 0.014/1.5 0.005/0.9 Deviations from idealized geometry
Average B factor 55 54.4 Bond lengths (A˚) 0.002 ± 0.000
No. of atoms Bond angles () 0.429 ± 0.022
Protein atoms 6,430 6,907 Impropers () 0.347 ± 0.047
Water molecules 166 Ramachandran plote (%)
Other molecules 21 Most favorable regions 79.7
No. of reflections Additional allowed regions 14.2
Working set 22,659 42,096 Generously allowed regions 4.3
Test set 1,213 2,124 Disallowed regions 1.8
Ramachandran plot Coordinate precision
Most favored regions (%) 88.2 92.7 Atomic rmsdf (A˚)
Additionally allowed (%) 11 7.3 Residues 1–45 for the WHEP domain
Generously allowed (%) 0.8 0 Heavy 1.081
Backbone 0.447
Residues 69–165 for the ABD
Heavy 1.468
Backbone 0.872
aNone of the structures exhibits distance violations greater than 0.3 A˚ or dihedral angle violations greater than 4.
bNumbers in parentheses represent the value for the highest resolution shell.
cRmerge = SjIi  Imj/SIi, where Ii is the intensity of the measured reflection and Im is the mean intensity of all symmetry related reflections.
dRcryst =SjjFobsj  jFcalcjj/SjFobsj, where Fobs and Fcalc are observed and calculated structure factors. Rfree =STjjFobsj  jFcalcjj/STjFobsj, where
T is a test data set of about 5% of the total reflections randomly chosen and set aside prior to refinement.
eThe program Procheck was used to assess the overall quality of the structures.
fThe precision of the atomic coordinates is defined as the average Rmsd between 20 final structures and the mean coordinates of the protein.
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Human HisRS and Internally Deleted Splice Variantmutant. Indeed, its structure is essentially identical to that of the
HisRS D507-509 (Figures 2B and S2B), and shows a dimeric
composition that agrees with the molecular weight determined
by size exclusion chromatography (Figure S2C).
According to the structure of human HisRS D1-53_507-509
(PDB: 4G85), the overall fold of the CD and ABD of human HisRS
is similar to its bacterial, archaeal and T. brucei and T. cruzi
orthologs (Figure 2C). The most prominent difference among
these structures is in the additional domain inserted between
conserved motifs 2 and 3 of the class II catalytic core. This inser-
tion domain increases in size from prokaryotes to eukaryotes,
and is not conserved in either sequence or structure between
prokaryotic and eukaryotic HisRSs (Figure S2D). With the excep-
tion of a missing a9 helix in the insertion domain of eukaryote1474 Structure 20, 1470–1477, September 5, 2012 ª2012 Elsevier Ltparasite homologs, the secondary structure elements of human
HisRS are similar to those of the parasite homologs. It was
previously proposed that the insertion domain may contact
the acceptor stem of the tRNA (Freist et al., 1999). Superpo-
sition of structural cores of human, T. brucei, T. cruzi and
T. thermophilus HisRS also reveals the orientation difference of
the insertion domains (Figure 2D).
StructureDetermination of the Splice Variant HisRSDCD
by NMR Spectroscopy
Similar to native HisRS, wild-type HisRSDCD forms oligomers
even in the presence of 1 mM DTT (Figure S3A). To avoid the
disulfide formation, the C-terminal Cys169 and Cys171 (corre-
sponding to C507 and C509 in HisRS) were mutated to serinesd All rights reserved
Figure 3. Structure Determination of the
Splice Variant HisRSDCD by NMR Spec-
troscopy
(A) Schematic of HisRSDCD* (2C2S_W94Q)
mutant employed for structural characterizations.
The mutational sites are labeled in red and the
corresponding C507, C509, and W432 residues in
the native HisRS sequence are also indicated.
(B) The 1H-15N HSQC spectrum of HisRSDCD*
used for structure determination.
(C) Backbone superimposition of 20 calculated
lowest-energy structures of the WHEP domain
and the ABD of HisRSDCD* are shown, and the
HisRSDCD* structure is presented below by
ribbon diagram. WHEP domain (red) and ABD
(green) are well-folded and linked by a flexible
loop.
(D) Superposition of NMR structures of
HisRSDCD* and of the WHEP domain alone (PDB:
1X59). Structures are shown in ribbon diagram.
Red: WHEP domain of HisRSDCD*, pink: 1X59.
(E) Superposition of human HisRS D1-53_507-509
crystal structure and HisRSDCD* NMR structure.
The W432 in HisRS FL was labeled in red. The
circled area including helix a15 and the preceding
loop had the most prominent differences (see also
Figure S2D). Structures are shown in ribbon dia-
gram. Orange: ABD of HisRSDCD*, Green: ABD of
HisRS FL, gray: CD of HisRS FL.
See also Table 1 and Figures S2 and S3.
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Human HisRS and Internally Deleted Splice Variant(2C2S, Figure 3A). The HisRSDCD_2C2S proteins were mostly
monomeric in solution (Figures S3A and S3B), and the 1H-15N
heteronuclear single quantum coherence (HSQC) spectrum
showed an increase in peak count andmore uniform peak shape
compared to that of the wild-type HisRSDCD (Figures S3C and
S3D). But the peak number was still less than expected and,
together with the presence of broadened peaks, we concluded
that this protein still had nonspecific interactions and was not
sufficiently homogeneous for structure determination. Based
on the solved crystal structure of HisRS, it seemed likely that
the absence of the CD in HisRSDCD exposed the hydrophobic
inter-domain interface of the ABD, leading to non-specific
hydrophobic interactions and thereby introducing heterogeneity.
To decrease the hydrophobicity, Trp94 (corresponding to
Trp432 in the numbering of the sequence of HisRS and located
at the center of the hydrophobic interface) was substituted
by the more hydrophilic Gln (Figure 3A). This substitution
greatly improved the protein homogeneity as demonstrated by
the 1H-15N HSQC spectrum, which displays well dispersed
peaks with a peak yield > 95% (Figure 3B). In addition, com-
paring HisRSDCD 2C2S_W94Q mutant (HisRSDCD*) to the
wild-type and 2C_2S mutant, the shared HSQC peaks of the
proteins exhibited no obvious chemical shifts, thus indicating
that the substitutions did not alter the protein conformationStructure 20, 1470–1477, September 5, 2012 ª(Figures S3C and S3E). Therefore, the
HisRSDCD* mutant was used for further
structural characterizations.
We first tried to solve the structure of
HisRSDCD* by X-ray crystallography,
but extensive trials failed to obtain welldiffracting crystals. Because the 15N-1H HSQC spectrum of
HisRSDCD* is well dispersed and contains only one set of peaks,
showing that this protein forms a well-folded structure in solu-
tion, we could determine its structure to a high resolution by
NMR spectroscopy (Figure 3B; Table 1; PDB: 2LW7). In contrast
to homodimeric HisRS, HisRSDCD* behaved as a monomer in
solution, which is probably due to the lack of the CD that facili-
tates dimerization of HisRS. The ensemble of 20 NMR structures
of HisRSDCD* are well defined, with a root-mean-square devia-
tion (RMSD) of 0.447 A˚ for backbone atoms and 1.081 A˚ for
heavy atoms of the WHEP domain, and a RMSD of 0.872 A˚ for
backbone atoms and 1.468 A˚ for heavy atoms of the ABD (Fig-
ure 3C). Its WHEP domain adopts an antiparallel bi-helical struc-
ture. (An NMR structure of a 73 amino acid peptide, comprised of
the first 60 amino acids of human HisRS and 13 amino acids
derived from a recombinant plasmid construct that was used,
is documented in the PDB [1X59]. According to our solution
structure, the WHEP domain of this peptide is identical to that
of the WHEP domain of HisRSDCD* that is shown in Figure 3D.)
The ABD of HisRSDCD* forms a compact mixed a/b fold. The
WHEP and ABD domains are connected by a 27 amino acid,
highly flexible linker (Figure 3C). No long-distance NOE cou-
plings between the residues of the two domains were found in
the NMR spectra. The lack of couplings indicates that the two2012 Elsevier Ltd All rights reserved 1475
Figure 4. Possible Association of HisRSDCD with IIM/ILD
Jo-1 antibodies from two different IIM patients react with recombinant human
HisRS FL (hsHisRS) and HisRSDCD, but not with E. coli HisRS (ecHisRS). The
optical density at 450 nm was used to monitor the formation of antibody
complexes in the ELISA. The ‘‘7B’’ stands for lot 7B04507 of Jo-1 antibodies
and ‘‘4L’’ stands for lot 4L34811. The titration assay by ELISAwas performed in
duplicate and data are represented as mean ± SEM.
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Human HisRS and Internally Deleted Splice Variantdomains do not make contacts. As a further support, we purified
the ABD (aa398-506) alone and, when comparing its HSQC
spectrum with that of the ABD in HisRSDCD*, these amino acids
showed largely the same chemical shifts (Figure S3F). Thus,
HisRSDCD* appears as a dumbbell-like structure with ‘‘free-
floating’’ N- and C-terminal domains. This structure appears
poised to interact with two different partners and, with the flex-
ible linker, to be able to adapt to a variable separation of these
partners.
In HisRSDCD*, the packing interactions of the ABD with the
CD have been released. Comparing the ABDs in the NMR struc-
ture of HisRSDCD* with that of the crystal structure of HisRS
D1-53_507-509, the overall folds remain the same (Figure 3E).
However, a prominent difference was found at helix a15 and
the loop preceding it (Figure S2D), which are rigidly packed
with the CD in HisRS. In HisRSDCD* this region becomes flexible
and moves inward, due to the lack the interaction with the CD.
Possible Association of HisRSDCD with IIM and ILD
As stated earlier, HisRS is associated with IIM and ILD. HisRS
or its constituent peptides have been implicated in the etiology
of these diseases. For patients with IIM or ILD, Jo-1 autoanti-
bodies target, in part, the N-terminal region of HisRS (Jura
et al., 2007; Martin et al., 1995; Raben et al., 1994). As might
be expected from its structure, we observed that Jo-1 antibodies
from patients react with HisRSDCD (Figure 4). In addition, Gran-
zyme B cleavage of autoantigens is suggested to contribute to
the initiation and propagation of autoimmunity, and it is note-
worthy that HisRS was amenable to Granzyme B cleavage
in vitro at the N-terminal sequence LGPD48, a tetrapeptide that
is also encompassed by HisRSDCD (Darrah and Rosen, 2010;
Levine et al., 2007). While the purpose of this study was not to
investigate the etiology of IIM and ILD that is associated with
HisRS, these results suggest that HisRSDCD should at least be
further considered in this regard.1476 Structure 20, 1470–1477, September 5, 2012 ª2012 Elsevier LtConclusions
We discovered an internal deletion splice variant of human
HisRS that completely and precisely ablates the CD and little
else. From investigations of the structures of HisRSDCD and
its parent HisRS, three prominent differences were noted. First,
in contrast to the dimeric structure shared by HisRSs throughout
evolution, HisRSDCD is a monomer. Second, the tight domain-
domain packing interactions seen in HisRS are absent in
HisRSDCD, which presents two ‘‘free-floating’’ domains loosely
tethered together by a 27 amino acid flexible linker. Third, the
release of packing interactions for the ABD of HisRSDCD engen-
ders a specific conformational change in the ABD. The existence
of an AARS variant that lacks a CD, and that has undergone
demonstrable changes in the tertiary and quaternary structures,
is highly suggestive of strong selective pressures to repurpose
HisRS.
EXPERIMENTAL PROCEDURES
The exon-skipping splicing events in the gene for human HisRS were
identified by deep sequencing of AARS-transcriptome enriched cDNA of
human tissues and cells. The splice variant HisRSDCD was validated by
PCR, and the endogenous protein was detected by western blot analysis.
The mRNA expression level of HisRSDCD in various human tissues was
analyzed by the qPCR method. Recombinant human HisRS, HisRSDCD,
and their variants were overexpressed in E. coli, purified, and subjected to
structural characterizations using X-ray crystallography and NMR tech-
niques. The binding of the HisRS proteins to patient Jo-1 antibodies were
analyzed by an enzyme-linked immunosorbent assay (ELISA). The detailed
description of the experimental procedures is provided in Supplemental
Experimental Procedures.
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